Japan's THE PHAGE raises $3.61M Series A for blood-sugar prediction AI
What's the deal? Tokyo-based THE PHAGEDealroom has a profile for this one. Try Dealroom → has raised US$4.38M (roughly $3.61 million) in its first Series A round through equity and debt financing. ITOCHU Technology VenturesDealroom has a profile for this one. Try Dealroom → led the round, with Tokio Marine & Nichido Fire InsuranceDealroom has a profile for this one. Try Dealroom → and Fukui Capital PartnersDealroom has a profile for this one. Try Dealroom → joining as new shareholders.
Existing backers Genesia VenturesDealroom has a profile for this one. Try Dealroom → and Vision IncubateDealroom has a profile for this one. Try Dealroom → — leads on the company's two prior rounds — added follow-on investment, while Shoko Chukin BankDealroom has a profile for this one. Try Dealroom → provided debt financing.
What's the endgame? Founded in 2021, THE PHAGE builds AI for personalised preventive healthcare using continuous glucose data. Its core technology, a continuous glucose monitoring foundation model (CGFM), applies the "foundation model" approach known from large language models to biometric data, aiming to predict blood-sugar changes and assess health risks.
The company says it will use the funds to expand its existing personalised prevention business and accelerate development of the model, targeting lifestyle-related diseases.
Why now? THE PHAGE says it has moved past the research and pilot stage into running AI commercially at scale. Chief executive officer Shohei Tokunaga said the company aims to spread its "Glucose Flight" product at home and abroad while establishing a pre-symptomatic health platform.
What else? THE PHAGE also agreed a capital and business alliance with Tokio Marine HoldingsDealroom has a profile for this one. Try Dealroom → to explore commercialising healthcare solutions across the Tokio Marine group, including preventing the worsening of lifestyle-related diseases.
The firm develops its technology alongside research institutions, including Chiba UniversityDealroom has a profile for this one. Try Dealroom → under professor Hideyoshi Kawakami.
What investors say: ITOCHU Technology Ventures partner Takeshi Abe said the large-scale blood-sugar data THE PHAGE has accumulated, and the AI built on it, have "the potential to significantly change the nature of preventive medicine." (translated from Japanese)
Genesia Ventures investment manager Koki Mizutani, who has backed the company since its pre-seed stage four years ago, said precision of the blood-sugar foundation model and product implementation had advanced steadily.
The signal: The round sits in the lower tier for its category by amount, but the backing of a corporate venture arm, a major insurer, and a government-linked bank points to institutional interest in data-driven preventive care. With continuous glucose monitoring spreading and Japan pushing "proactive preventive medicine," THE PHAGE is betting that glucose data becomes a foundation for broader health management — at home and in global markets.
Read more: prtimes.jp
Image credit: tedeytan
